Resolution criteria
This market will resolve to "Yes" if, by December 31, 2030, a peer-reviewed clinical trial demonstrates that GLP-1 receptor agonists significantly reduce osteoarthritis symptoms in humans. The trial must be published in a reputable medical journal and show statistically significant improvements in osteoarthritis symptoms compared to a control group. The primary outcome measures should include validated assessments of pain, physical function, and/or structural changes in the affected joints. If no such study is published by the specified date, the market will resolve to "No". If such a study sets out to investigate this and finds no significant reduction of such symptoms before market end date the market also resolves "No".
I’ve actually been following GLP-1 research for my dad’s knee arthritis. My dad’s been dealing with daily discomfort for years, and I’ve seen how it limits his walks with my toddler son. I’m planning to chat with his doctor soon, but first I’ll call the KGH phone number to ask about ongoing clinical trials or specialists focusing on GLP-1 treatments in osteoarthritis.